Chanchal Goyal

Chanchal Goyal

Auto-generated profile, based on publicly available information

Chanchal Goyal

Centre for Evidence-based Guidelines , ICMR-DHR , New Delhi , India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Closed access
VVVinu Vij
Vinu Vij
KDKalyani Deshmukh
Kalyani Deshmukh
MVMathavaswami Vijayageetha
Mathavaswami Vijayageetha
CGChanchal Goyal
Chanchal Goyal
JGJyotsna Gumashta
Jyotsna Gumashta
APAravind Gandhi P
Aravind Gandhi P

29 May 2025 in Journal of Perinatal Medicine
Verified
Journal Article
Open access
PDF file
AYAnita Yadav
Anita Yadav
PYPriyanka Yadav
Priyanka Yadav
KDKalyani P. Deshmukh
Kalyani P. Deshmukh
AKAnusha Kamath
Anusha Kamath
CGChanchal Goyal
Chanchal Goyal
APAravind Gandhi P
Aravind Gandhi P
Objectives: Maternal oral hydration therapy is a non-invasive approach to improving AFI, but its effectiveness remains uncertain. This systematic review and meta-analysis were therefore undertaken to assess the effectiveness of maternal oral hydration therapy in increasing AFI in pregnancies complicated by oligohydramnios and to evaluate its impact on maternal and neonatal outcomes. Methods: A systematic search of Cochrane Library, Embase, PubMed, Scopus, and Web of Science was conducted. Eligible studies included randomized controlled trials (RCTs), quasi-experimental studies, and analytical observational studies. All studies published till 22 November 2024 in the above databases were included. No restrictions were placed on geographic location or study setting. Two reviewers independently undertook the screening. Relevant studies were identified, screened, and duplicates removed using NESTED Knowledge. Risk of bias was assessed using NOS, JBI, and ROBINS-I tools. Statistical analyses, including meta-analysis using a random-effects model, were conducted in R Studio and Comprehensive Meta-Analysis (CMA) software. Heterogeneity was assessed using the I 2 statistic. Results: Out of the 12 included studies four qualified for meta-analysis. Pooled results showed a significant increase in AFI at 2 hours (mean difference: 0.996; 95 % CI: 0.781–1.210), 1 day (0.853; 95 % CI: 0.532–1.174), 2 days (1.649; 95 % CI: 0.943–2.356), and 1 week (2.232; 95 % CI: 0.943–3.520). However, high heterogeneity was observed due to variations in fluid type, volume, and frequency. Conclusions: It can be concluded that oral hydration therapy significantly increases AFI and is a simple intervention for managing oligohydramnios, especially in resource-limited settings.

25 January 2025 in Evidence Public Health
Verified
Journal Article
Open access
PDF file
AGAnkita Gaonkar
Ankita Gaonkar
SRShree Rath
Shree Rath
RSRahini S
Rahini S
MJManav Jain
Manav Jain
RVRaman Swathy Vaman
Raman Swathy Vaman
KAKrishna Chaitanya Amerneni
Krishna Chaitanya Amerneni
Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative technologies in healthcare, particularly in medical diagnostics. This review explores the role of AI and ML in revolutionizing disease detection, treatment planning, and personalized healthcare. AI technologies, including deep learning (DL), natural language processing (NLP), and advanced data analytics, enable the rapid and accurate processing of complex medical datasets such as imaging, genetic information, and electronic health records (EHRs). By identifying subtle patterns and abnormalities, AI systems enhance diagnostic accuracy in areas such as oncology, cardiology, neurology, dermatology, and infectious diseases. The integration of AI in cancer diagnosis, for instance, has improved early detection through advanced imaging analysis using convolutional neural networks (CNNs) and deep learning models. Similarly, in cardiovascular diseases, AI enhances electrocardiogram (ECG) analysis and risk stratification, enabling early intervention. Neurological disorders such as Alzheimer's and Parkinson's benefit from AI tools that analyze neuroimaging, speech, and motor patterns for early diagnosis and progression monitoring. In diabetes management, ML models predict disease onset, personalize treatment plans, and improve blood glucose monitoring. Dermatological and ophthalmological applications leverage AI-driven image recognition tools to diagnose skin lesions, diabetic retinopathy, and glaucoma with high precision. Despite its potential, the adoption of AI in healthcare faces challenges, including data privacy concerns, algorithmic bias, and regulatory hurdles. Addressing these issues through robust validation, transparency, and ethical frameworks is essential for wider implementation. This review highlights the future prospects of AI in healthcare, such as precision medicine, wearable technology, and AI-driven telemedicine, emphasizing its potential to enhance efficiency, reduce costs, and improve patient outcomes. As AI technologies continue to evolve, they promise a more accurate, accessible, and personalized approach to medical diagnosis and treatment.

14 January 2026 in Journal of Perinatal Medicine
Verified
Journal Article
Open access
PDF file
NMNandini Shashikant Malshe
Nandini Shashikant Malshe
AKAnuva Kapoor
Anuva Kapoor
KDKalyani P. Deshmukh
Kalyani P. Deshmukh
CGChanchal Goyal
Chanchal Goyal
APAravind Gandhi P
Aravind Gandhi P
Objectives: Preterm birth is associated with a higher risk of mortality. In 2020, the global incidence of preterm births was reported at 9.9 per 100 live births. This meta-analysis was undertaken to evaluate the effect of preterm birth on mortality among various age groups. Methods: A thorough search was done on four electronic databases: “PubMed, Scopus, Web of Science, and Embase”. Adhering to PRISMA 2020 guidelines, observational analytical studies published till 4th December 2024 were included. Screening of the studies was done by two independent reviewers in two stages: title/abstract, followed by full text review of the advanced articles. It was followed by data extraction. Study quality was assessed with the Newcastle Ottawa Scale. Meta-analysis using a random-effects model was done in R Studio. PROSPERO ID: CRD42024622282. Results: Database search yielded 1775 unique studies. 23 studies met the final predefined eligibility criteria. Preterm babies showed an increased risk of mortality compared to term babies with a pooled relative risk of 6.12 (95 % CI: 3.16–11.84) for neonatal mortality, 11.84 (95 % CI: 6.88–20.37) for infant mortality and 1.88 (95 % CI: 1.24–2.83) for 1–5 year. However, it was similar in adult mortality with a pooled relative risk of 1.21 (95 % CI: 0.07–20.12). Conclusions: Preterm birth is strongly associated with increased risks of childhood mortality, especially in extreme and very preterm infants, but the risk persists even for late preterms.

20 August 2025 in Clinical Obesity
Verified
Journal Article
Closed access
GPGeeta Pardeshi
Geeta Pardeshi
UKUddhav T. Kumbhar
Uddhav T. Kumbhar
MKMogan Kaviprawin
Mogan Kaviprawin
ADAninda Debnath
Aninda Debnath
ADAshok Kumar Dubey
Ashok Kumar Dubey
APAravind Gandhi P
Aravind Gandhi P

25 January 2025 in Evidence Public Health
Verified
Journal Article
Open access
PDF file
MAMona Thangamma Ag
Mona Thangamma Ag
SRShree Rath
Shree Rath
ASAndria Sirur
Andria Sirur
VUVijaya Kumar Uthakalla
Vijaya Kumar Uthakalla
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
SYSree Sudha T Y
Sree Sudha T Y
Background: Colorectal cancer, one of the most prevalent cancers globally, originates from polyps in the colon or rectum, which can develop into cancer over time. It remains a leading cause of cancer-related deaths, imposing significant economic and healthcare burdens. As the incidence of colorectal cancer continues to rise, particularly in developing healthcare systems, understanding the economic impact of treatment options is critical for informing clinical decisions and shaping healthcare policies. Methods: Following PRISMA guidelines, an extensive literature search was conducted through databases including PubMed, Embase, and Scopus up to 7 October 2024. The inclusion criteria targeted studies utilizing cost-effectiveness analysis frameworks like Markov and Partitioned-Survival models, comparing fruquintinib to other cancer treatments. Key outcome measures focused on Incremental Cost-Effectiveness Ratios and Quality-Adjusted Life Years. Results: Of the 49 articles screened, seven studies were eligible for inclusion. These studies provided a detailed economic evaluation of Fruquintinib against Regorafenib, placebo, and best supportive care. Notably, Fruquintinib was cost-effective in the Chinese healthcare setting with an ICER of $26,508 per QALY compared to $35,607 for Regorafenib. However, it did not meet cost-effectiveness thresholds when compared with placebo, with an ICER exceeding three times the GDP per capita in China, reflecting the economic challenges of implementing new cancer treatments. Conclusion: Fruquintinib shows promise as a cost-effective treatment for metastatic colorectal cancer, particularly in healthcare settings like China, providing significant QALY gains compared to traditional therapies. However, its adoption is highly dependent on local economic thresholds and healthcare systems. While this study underscores the need to integrate economic and clinical outcomes in cancer treatment decisions, the drug's approval and data are currently limited to China, making it difficult to conclude its cost-effectiveness globally